GLP-1 weight loss users cut food spending in their first 3 months, says Circana. But by the end of year one, spending is ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.